Hobbs Wealth Management LLC bought a new position in Eli Lilly and Company (NYSE:LLY - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 1,447 shares of the company's stock, valued at approximately $1,117,000. Eli Lilly and Company makes up approximately 1.3% of Hobbs Wealth Management LLC's portfolio, making the stock its 16th largest holding.
A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Coign Capital Advisors LLC bought a new stake in Eli Lilly and Company during the 4th quarter valued at about $600,000. Glass Jacobson Investment Advisors llc boosted its stake in Eli Lilly and Company by 4.4% during the 4th quarter. Glass Jacobson Investment Advisors llc now owns 355 shares of the company's stock valued at $274,000 after purchasing an additional 15 shares during the last quarter. Heritage Trust Co bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at $1,969,000. Tandem Wealth Advisors LLC increased its holdings in Eli Lilly and Company by 7.2% in the 4th quarter. Tandem Wealth Advisors LLC now owns 700 shares of the company's stock worth $540,000 after buying an additional 47 shares in the last quarter. Finally, Jaffetilchin Investment Partners LLC raised its position in Eli Lilly and Company by 1.8% in the 4th quarter. Jaffetilchin Investment Partners LLC now owns 14,885 shares of the company's stock worth $11,491,000 after buying an additional 268 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on the stock. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their target price for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Morgan Stanley dropped their price objective on shares of Eli Lilly and Company from $1,146.00 to $1,124.00 and set an "overweight" rating on the stock in a report on Wednesday, April 9th. Leerink Partners set a $950.00 target price on shares of Eli Lilly and Company in a report on Friday, January 17th. StockNews.com upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Finally, Berenberg Bank set a $970.00 price objective on Eli Lilly and Company in a research note on Thursday, January 16th. Two investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and an average target price of $1,012.00.
Get Our Latest Research Report on LLY
Insider Buying and Selling at Eli Lilly and Company
In related news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.13% of the stock is currently owned by corporate insiders.
Eli Lilly and Company Price Performance
Shares of NYSE LLY traded down $1.84 during midday trading on Tuesday, reaching $752.51. 1,152,934 shares of the stock traded hands, compared to its average volume of 3,378,000. The stock has a market capitalization of $713.51 billion, a PE ratio of 64.26, a P/E/G ratio of 1.40 and a beta of 0.51. The company's 50 day moving average is $835.24 and its 200 day moving average is $822.00. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.
About Eli Lilly and Company
(
Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Read More
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
